{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:36:44Z","timestamp":1793317004004,"version":"4.5.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jogc.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Obstetrics and Gynaecology Canada"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1016\/s1701-2163(16)34026-9","type":"journal-article","created":{"date-parts":[[2016,2,23]],"date-time":"2016-02-23T22:55:05Z","timestamp":1456268105000},"page":"1146-1148","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":99,"title":["Does Treatment With Bisphosphonates Endanger the Human Pregnancy?"],"prefix":"10.1016","volume":"30","author":[{"given":"Nada","family":"Djokanovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chagit","family":"Klieger-Grossmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gideon","family":"Koren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/S1701-2163(16)34026-9_bb0685","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1196\/annals.1402.089","article-title":"Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy","volume":"1117","author":"Russell","year":"2007","journal-title":"Ann NY Acad Sci"},{"issue":"1","key":"10.1016\/S1701-2163(16)34026-9_bb0690","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3109\/07853899708998743","article-title":"Bisphosphonates: preclinical aspects and use in osteoporosis","volume":"29","author":"Fleisch","year":"1997","journal-title":"Ann Med"},{"issue":"12","key":"10.1016\/S1701-2163(16)34026-9_bb0695","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s00228-001-0411-8","article-title":"A pharmacokinetic and pharmacodynamic model for intravenous bisphosphonate (pamidronate) in osteoporosis","volume":"57","author":"Cremers","year":"2002","journal-title":"Eur J Clin Pharmacol"},{"issue":"Suppl 2S","key":"10.1016\/S1701-2163(16)34026-9_bb0700","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1542\/peds.2006-2023H","article-title":"Bisphosphonates: mode of action and pharmacology","volume":"119","author":"Russel","year":"2007","journal-title":"Pediatrics"},{"issue":"5","key":"10.1016\/S1701-2163(16)34026-9_bb0705","first-page":"654","article-title":"Reproduction toxicity studies with pamidronate","volume":"42","author":"Graepel","year":"1992","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/S1701-2163(16)34026-9_bb0710","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/(SICI)1096-9926(199908)60:2<68::AID-TERA10>3.0.CO;2-H","article-title":"Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats","volume":"60","author":"Patlas","year":"1999","journal-title":"Teratology"},{"key":"10.1016\/S1701-2163(16)34026-9_bb0715","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1006\/taap.1993.1148","article-title":"Effects of the bisphosphonate, alendronate, on parturition in the rat","volume":"121","author":"Minsker","year":"1993","journal-title":"Toxicol Appl Pharmacol"},{"issue":"3","key":"10.1016\/S1701-2163(16)34026-9_bb0720","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/bdra.10016","article-title":"No effects of bisphosphonates on the human fetus","volume":"67","author":"Rutgers-Verhage","year":"2003","journal-title":"Birth Defects Res (Part A): Clin Mol Teratol"},{"key":"10.1016\/S1701-2163(16)34026-9_bb0725","first-page":"359","article-title":"Fetal outcome after intrauterine exposure to bisphosphonates","volume":"70","author":"Levy","year":"2004","journal-title":"Birth Defects Res Part A: Clin Mol Teratol"},{"issue":"4","key":"10.1016\/S1701-2163(16)34026-9_bb0730","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.reprotox.2006.05.009","article-title":"The outcome of pregnancy following pre-pregnancy or early pregnancy alendronate treatment","volume":"22","author":"Ornoy","year":"2006","journal-title":"Reprod Toxicol"},{"key":"10.1016\/S1701-2163(16)34026-9_bb0735","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1136\/ard.49.11.955-a","article-title":"Antenatal administration of aminopropylidene diphosphonate","volume":"49","author":"Dunlop","year":"1990","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/S1701-2163(16)34026-9_bb0740","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0936-6555(05)80667-3","article-title":"Malignant hypercalcaemia in pregnancy and antenatal administration of intravenous pamidronate","volume":"8","author":"Illidge","year":"1996","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"3Pt 2","key":"10.1016\/S1701-2163(16)34026-9_bb0745","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1097\/01.AOG.0000209183.39581.e9","article-title":"Malignant hypercalcemia in pregnancy: effect of pamidronate on uterine contractions","volume":"108","author":"Culbert","year":"2006","journal-title":"Obstet Gynecol"},{"issue":"1","key":"10.1016\/S1701-2163(16)34026-9_bb0750","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ygyno.2004.06.037","article-title":"Combined chemotherapy and radiotherapy during conception and first two trimesters of gestation in a woman with metastatic breast cancer","volume":"95","author":"Andreadis","year":"2004","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/S1701-2163(16)34026-9_bb0755","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1056\/NEJMp038103","article-title":"Do bisphosphonates make children\u2019s bones better or brittle?","volume":"349","author":"Marini","year":"2003","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/S1701-2163(16)34026-9_bb0760","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s00431-003-1298-4","article-title":"The role of bisphosphonates in diseases of childhood","volume":"162","author":"Srivastava","year":"2003","journal-title":"Eur J Pediatr"},{"issue":"10","key":"10.1016\/S1701-2163(16)34026-9_bb0765","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1359\/JBMR.040711","article-title":"Maternal and fetal outcome after long-term pamidronate treatment before conception: a report of two cases","volume":"19","author":"Munns","year":"2004","journal-title":"J Bone Miner Res"},{"issue":"6","key":"10.1016\/S1701-2163(16)34026-9_bb0770","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1210\/jc.2005-2548","article-title":"Maternal and infant outcome after pamidronate treatment of polyostotic fibrous dysplasia and osteogenesis imperfecta before conception: a report of four cases","volume":"91","author":"Chan","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/S1701-2163(16)34026-9_bb0775","first-page":"344","article-title":"Maternal and fetal outcome of pamidronate treatment before conception: a case report","volume":"25","author":"Cabar","year":"2007","journal-title":"Clin Exp Rheumatol"}],"container-title":["Journal of Obstetrics and Gynaecology Canada"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1701216316340269?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1701216316340269?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T15:18:31Z","timestamp":1761664711000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1701216316340269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":19,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["S1701216316340269"],"URL":"https:\/\/doi.org\/10.1016\/s1701-2163(16)34026-9","relation":{},"ISSN":["1701-2163"],"issn-type":[{"value":"1701-2163","type":"print"}],"subject":[],"published":{"date-parts":[[2008,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Does Treatment With Bisphosphonates Endanger the Human Pregnancy?","name":"articletitle","label":"Article Title"},{"value":"Journal of Obstetrics and Gynaecology Canada","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S1701-2163(16)34026-9","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Society of Obstetricians and Gynaecologists of Canada. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}